Galapagos NV (GLPG) Says Regulatory Discussions Over DIVERSITY Phase 3 Completed
- S&P little changed as energy weighs but financials edge up
- Nestle Said Examining Takeover of Mead Johnson (MJN) - Source
- Fed's Yellen says 'makes sense' to gradually raise interest rates
- UPDATE: Fed Beige Book: Wages gain modestly in most areas amid tight job market
- Mallinckrodt (MNK) Announces FTC Settlement
Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.
Galapagos NV (Nasdaq: GLPG) reports the successful completion of discussions with the regulatory authorities in the US and Europe to initiate the DIVERSITY Phase 3 study in Crohn's disease and the SELECTION Phase 2b/3 study in ulcerative colitis with filgotinib. Both studies will investigate efficacy and safety of 100 mg and 200 mg filgotinib once-daily compared to placebo in patients with moderately to severely active disease including those with prior antibody therapy failure. First dosing is expected in Q4'16.
Both studies will recruit approximately 1,300 patients each from the US, Europe, Latin America, Canada, and Asia/Pacific. The SELECTION Phase 2b/3 study in ulcerative colitis will include a futility analysis, serving as the Phase 2b part of this integrated Phase 2b/3 study. Men and women in both the SELECTION and DIVERSITY studies will be randomized to receive placebo, 100 mg or 200 mg filgotinib. In the US, males may receive 200 mg if they failed at least one anti-TNF and vedolizumab. The filgotinib Phase 3 program will also contain a dedicated male patient testicular safety study.
"The outcome of the discussions with US and national European regulatory authorities enables our collaboration partner Gilead to further evaluate filgotinib in IBD," said Dr Piet Wigerinck, Chief Scientific Officer at Galapagos. "The improvements in clinical signs, quality of life, and endoscopy in Crohn's patients reported in the FITZROY Phase 2 study support this next step."
Galapagos and Gilead entered into a global collaboration for the development and commercialization of filgotinib in inflammatory indications. Gilead initiated the FINCH Phase 3 program in rheumatoid arthritis in August 2016.
Filgotinib is an investigational therapy and its efficacy and safety have not been established.
For information about the studies with filgotinib in IBD: www.clinicaltrials.govFor more information about filgotinib: www.glpg.com/filgotinib
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Dr. Walid Abi-Saab joins Galapagos as Chief Medical Officer
- Delcath Systems (DCTH) Says New Outcomes Using Melphalan/HDS to Treat Unresectable Metastatic Ocular Melanoma Accepted for Oral Presentation
- Navient (NAVI) Rejects CFPB Ultimatum to Settle
Create E-mail Alert Related CategoriesCorporate News, FDA, Management Comments
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!